Joseph L. Izzo Jr.

Dr. Joseph L. Izzo Jr.


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2011 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
PDF file
JJJoseph L. Izzo Jr.
Joseph L. Izzo Jr.
JRJr
Jr
JLJoseph L.
Joseph L.

1 September 2004 in Medical Clinics of North America
Verified
Journal Article
Closed access
JJJoseph L. Izzo Jr.
Joseph L. Izzo Jr.
AGAlan H. Gradman
Alan H. Gradman

1 March 2008 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
YAYves Allemann
Yves Allemann
BFBelen Fraile
Belen Fraile
MLMichel Lambert
Michel Lambert
MBMichaela Barbier
Michaela Barbier
PFPhilippe Ferber
Philippe Ferber
JJJoseph L. Izzo Jr.
Joseph L. Izzo Jr.
In this randomized, double‐blind, multicenter study, patients whose blood pressure (BP) was uncontrolled by monotherapy were switched directly to amlodipine/valsartan 5/160 mg (n=443) or 10/160 mg (n=451). After 16 weeks, BP control (levels <140/90 mm Hg or <130/80 mm Hg for diabetics) was achieved in 72.7% (95% confidence interval [CI], 68.6–76.9) of patients receiving amlodipine/valsartan 5/160 mg and in 74.8% (95% CI, 70.8–78.9) receiving amlodipine/valsartan 10/160 mg. Incremental reductions from baseline in mean sitting systolic and diastolic BP were significantly greater with the higher dose (20.0±0.7 vs 17.5±0.7 mm Hg; P=.0003 and 11.6±0.4 vs 10.4±0.4 mm Hg; P=.0046). Incremental BP reductions were also achieved with both regimens irrespective of previous monotherapy, hypertension severity, diabetic status, body mass index, and age. Peripheral edema was the most frequent adverse event. These results provide support for the BP‐lowering benefits of complementary antihypertensive therapy with amlodipine and valsartan in patients with hypertension uncontrolled by previous monotherapy.

12 July 2016 in American Journal of Hypertension
Verified
Journal Article
Closed access
PDF file
BGBenjamin Gavish
Benjamin Gavish
JJJoseph L. Izzo Jr.
Joseph L. Izzo Jr.
Interest in arterial stiffness has been fueled by the scientific and clinical implications of its “vicious cycle” relationship with aging and systolic blood pressure. In physical terms, stiffness is the slope of the relationship between an artery’s distending pressure and its cross-sectional area or volume. Pulse wave velocity (PWV, in m/s), the most common arterial stiffness indicator, is usually measured by the foot-to-foot time and distance method and is proportional to [stiffness × area (or volume)]1/2 at a given pressure. Its intrinsic pressure dependency and other flaws in current PWV methods limit its utility. In contrast, the arterial stiffness–arterial pressure relationship is near-linear, with a slope β, the exponent of the curvilinear arterial pressure–arterial volume relationship. The concept of arterial stiffening is related to β and describes a more functionally relevant aspect of arterial behavior: the change in stiffness for a given change in pressure. Arterial stiffening can be estimated from the variability of within-individual BP measurements (24-h ambulatory, home BP, or BP measured at different arm heights) and can be expressed as the pulse stiffening ratio (PSR) = [systolic stiffness]/[diastolic stiffness] or the ambulatory arterial stiffness index (AASI or its symmetric form, sAASI). High arterial stiffness (PWV) and stiffening (β, stiffness index, cardio-ankle vascular index, AASI, and PSR) are associated with increased cardiovascular disease risk, but it remains unclear whether these indicators are useful in improving medical care quality; the standard of care remains stringent BP control.

18 November 2025 in Circulation
Verified
Journal Article
Closed access
DBDavid D. Berg
David D. Berg
SPSiddharth M. Patel
Siddharth M. Patel
PHPaul Haller
Paul Haller
ACAbby L. Cange
Abby L. Cange
MPMichael G. Palazzolo
Michael G. Palazzolo
SWStephen D. Wiviott
Stephen D. Wiviott
BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of in-hospital initiation of dapagliflozin (10 mg daily) in patients hospitalized for HF. The primary efficacy outcome was a composite of time to cardiovascular death or worsening HF through 2 months. Key safety outcomes included symptomatic hypotension and worsening kidney function. A prespecified meta-analysis of randomized trials evaluating initiation of SGLT2 inhibitors in patients hospitalized for HF was performed. RESULTS: Of 2401 patients (median age, 69 [Q1–Q3, 58–77] years, 815 [33.9%] women, 448 [18.7%] Black race, 1717 [71.5%] left ventricular ejection fraction ≤40%, 1074 [44.7%] newly diagnosed HF) randomized between September 2020 and March 2025, 1218 were assigned to dapagliflozin and 1183 to placebo. The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68–1.08]; P =0.20). A worsening HF event occurred in 115 (9.4%) and 122 (10.3%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.91 [95% CI, 0.71–1.18]). Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48–1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43–1.00]). The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively. In a meta-analysis of patients hospitalized for HF, SGLT2 inhibitors reduced the early risk of cardiovascular death or worsening HF (HR, 0.71 [95% CI, 0.54–0.93] P =0.012) and of all-cause death (HR, 0.57 [95% CI, 0.41–0.80]; P =0.001). CONCLUSIONS: In this trial, in-hospital initiation of dapagliflozin did not significantly reduce the risk of cardiovascular death or worsening HF through 2 months in hospitalized HF patients. However, the totality of randomized clinical trial data suggests that in-hospital initiation of SGLT2 inhibitors may reduce the early risk of cardiovascular death or worsening HF and of all-cause mortality. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04363697.

24 September 2009 in Journal of Human Hypertension
Verified
Journal Article
Closed access
KRK J Radke
K J Radke
JJJoseph L. Izzo Jr.
Joseph L. Izzo Jr.